Active substance
Cefradine
- SFDA 10
- US FDA 17
- NHS prices 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| JULPHACEF 1GM I.M.-I.V. INJECTION | 1 g | Solution for injection · Intravenous use | 1 Vial | SAR 5.55 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| CEFRAMED 250MG CAPSULES | 250 mg | Capsule · Oral use | 20 Blister | SAR 24.00 | Generic · Prescription | MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES | Withdrawn by MAH · Not Marketed |
| CEFRAMED 500MG CAPSULES | 500 mg | Capsule · Oral use | 20 Blister | SAR 41.70 | Generic · Prescription | MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES | Invalid · Not Marketed |
| ESKACEF CAPS 250MG | 250 mg | Capsule, hard · Oral use | 20 Blister | SAR 29.60 | NCE · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| ESKACEF CAPS 500MG | 500 mg | Capsule, hard · Oral use | 20 Blister | SAR 33.20 | NCE · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| ESKACEF SUSP 125MG-5ML | 25 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 18.30 | NCE · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| ESKACEF SUSP 250MG-5ML | 50 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 27.20 | NCE · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| VELOSEF 1GM VIAL | 1 g | Solution for injection · Intravenous use | 15 Vial | SAR 9.50 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| VELOSEF 250MG\5ML SUSPENSION | 50 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 30.20 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| VELOSEF 500MG CAPSULE | 500 mg | Capsule · Oral use | 12 Blister | SAR 45.20 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VELOSEF '125' | 125MG/5ML | for suspension · oral | APOTHECON | Discontinued | 19 Aug 1974 |
| VELOSEF '250' | 250MG/5ML | for suspension · oral | APOTHECON | Discontinued | 19 Aug 1974 |
| VELOSEF | 250MG; 500MG | capsule · oral | APOTHECON | Discontinued | 19 Aug 1974 |
| ANSPOR | 250MG; 500MG | capsule · oral | GLAXOSMITHKLINE | Discontinued | 1 Oct 1974 |
| ANSPOR | 125MG/5ML; 250MG/5ML | for suspension · oral | GLAXOSMITHKLINE | Discontinued | 15 Oct 1974 |
| VELOSEF | 250MG/VIAL; 500MG/VIAL; 2GM/VIAL; 1GM/VIAL; 4GM/VIAL | injectable · injection | APOTHECON | Discontinued | 9 Feb 1977 |
| CEPHRADINE | 250MG; 500MG | capsule · oral | TEVA | Discontinued | 9 Jan 1987 |
| CEPHRADINE | 125MG/5ML; 250MG/5ML | for suspension · oral | TEVA | Discontinued | 9 Jan 1987 |
| CEPHRADINE | 250MG | capsule · oral | BARR | Discontinued | 22 Apr 1988 |
| CEPHRADINE | 500MG | capsule · oral | BARR | Discontinued | 22 Apr 1988 |
| CEPHRADINE | 125MG/5ML | for suspension · oral | BARR | Discontinued | 19 May 1988 |
| CEPHRADINE | 250MG/5ML | for suspension · oral | BARR | Discontinued | 19 May 1988 |
| CEPHRADINE | 250MG; 500MG | capsule · oral | IVAX SUB TEVA PHARMS | Discontinued | |
| CEPHRADINE | 250MG; 500MG | capsule · oral | VITARINE | Discontinued | |
| VELOSEF | 1GM | tablet · oral | BRISTOL MYERS SQUIBB | Discontinued | |
| VELOSEF '250' | 250MG | capsule · oral | ERSANA | Discontinued | |
| VELOSEF '500' | 500MG | capsule · oral | ERSANA | Discontinued |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Cefradine 250mg capsules | £21.86 | 20 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Cefradine 500mg capsules | £12.50 | 20 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.